Navigation Links
Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
Date:3/13/2008

Summary: Genmab's Acquisition of PDL BioPharma's Antibody Manufacturing

Facility has Closed.

COPENHAGEN, Denmark and REDWOOD CITY, California, March 14 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and PDL BioPharma, Inc. (Nasdaq: PDLI) today announced the closing of the previously announced transaction under which Genmab has acquired PDL's antibody manufacturing facility located in Brooklyn Park, Minnesota, USA for USD 240 million in cash. The transaction was first announced on February 21, 2008.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

About PDL

PDL BioPharma, Inc. is a biopharmaceutical company focused on the discovery and development of novel antibodies in oncology and select immunologic diseases. For more information, please visit http://www.pdl.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or perform
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
2. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
3. Medarex Announces Completion of Sale of Shares in Genmab A/S
4. Genmabs Financial Calendar for 2008
5. Genmab Reaches Milestones in Ofatumumab Collaboration
6. Genmab Announces HuMax-CD32b Pre-Clinical Program
7. Roche Files IND for Second Genmab Antibody
8. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
9. Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
10. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
11. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , SINGAPORE, Dec. 2 S*BIO Pte ...l oral JAK2 inhibitor, SB1518, at The American Soc...ion in New Orleans. ,, Data will be presented o...ation trial of SB1518 detailing its safety, tolera... profile in dose levels ranging from 100 to 600 mg...
(Date:12/2/2009)..., SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The w... are in turmoil and uncertainty is part of many,bu...rma industry has been,relatively immune to the eco...ation. , During the midst of the difficul...n & Johnson inaugurated an R&D center in S...
(Date:12/1/2009)...NCLINE VILLAGE, Nev., Dec. 1 /PRNewswire-FirstCall...day announced revenue guidance for the fourth quar...illion, as compared with $69 million for the fourt... results was the first of two installment payments...fourth quarter 2008 results was a one-time $1.8 mi...
(Date:12/1/2009)...PLYMOUTH, Mass., Dec. 1 Harvest Te... today results from the company sponsored 60-patie...ical Center in Chennai, India using the company,s ...able Critical Limb Ischemia (CLI). Sri Ramachandra...-associated institution based in Chennai, India an...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
...VER, Mass., Oct. 8 Millstone Medical Outsourcing,...cility in Fall River, MA,to accommodate growing bu...w for additional clean room operations. The new fa...,000 square feet of space that allows,increased ca...c cleaning,and sterile and non-sterile packaging. ...
...HMOND, Calif., Oct. 8 Transcept Pharmaceuticals,I...pany, announced today,that Thomas P. Soloway, Seni...cheduled to present at the Natixis Bleichroeder Se...y on Monday, October 13, 2008 at 9:30 AM,Eastern T...e available at, http://www.wsw.com/webcast/nblr2/t...
...e Review With Drs. William F. Fearon, Morton J. Ke...the Highlights, WILMINGTON, Massachusetts, Octobe...optimizing patient outcomes is the topic,of multip...cular,Therapeutics symposium, TCT 2008, which will...Medical Systems, the first company to develop syst...
Other Biology Technology:Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity 2Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference 2Radi Medical Systems Announces Schedule for TCT 2008 2
(Date:12/3/2009)...eve that staph infections are caused by many bacte...The signaling process is called quorum sensing bec...ocess. , But the Jeff Brinker research group has...ection, when bacteria switch from a harmless to a ...is individual process can be stopped by the applic...
(Date:12/3/2009)...evels for the past three years in the troposphere ... area near Valladolid. The results, which are the ... that the levels rose "significantly" between 2002...eteorologists have been trying to find out about c...lved in the troposphere over various urban and rur...
(Date:12/2/2009)...o men have a more difficult time quitting smoking ...re, but acculturation has no affect on Latinas odd...re published in Cancer Epidemiology, Biomarkers &...n for Cancer Research. The December issue has a sp... smoking cessation differently for Latino men and ...
Breaking Biology News(10 mins):Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3CO2 levels rising in troposphere over rural areas 2Acculturation affects smoking cessation success among Latinos 2Cradle and birthday of dog identified 9751 1Hard To Treat Diseases 28HTDS PK 29 Stem Cells and Regenerative Medicine 4931 1Hard To Treat Diseases 28HTDS PK 29 Stem Cells and Regenerative Medicine 4931 2Hard To Treat Diseases 28HTDS PK 29 Stem Cells and Regenerative Medicine 4931 3Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 1Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 2Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 3Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 4Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 5Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 6Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 7Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 8
...A study financed by the BBVA Foundation and conduc...uria Marb from the Mediterranean Institute for Ad...slands) has allowed the first-time formulation of ...plant communities, showing how plants assure the s...a day or are prolonged over centuries. , The rese...
...A joint Canadian-American research team have, for ...ations in fish respond directly to changes in atmo...ional teams research began in 2001 at the Experime...this weeks Proceedings of the National Academy of ...icult to establish because of all the other factor...
...GREENBELT, Md. -- The NASA-managed Sea-viewing Wid...d into orbit around Earth in 1997 and took its fir...e satellite,s data has proved instrumental in coun...picture of a changing climate. NASA recognized the...s at the Goddard Space Flight Center in Greenbelt,...
Other Biology News:A study proposes a new universal rule to explain the equilibrium of plant populations 2International team shows mercury concentrations in fish respond quickly to increased deposition 2NASA celebrates a decade observing climate impacts on health of world's oceans 2NASA celebrates a decade observing climate impacts on health of world's oceans 3
Random DNA mutagenesis Service from Yorkshire Bioscience Ltd
...ed solution for scheduling, performing and documen...ing for all pipettes and liquid handling devices. ...orts all gravimetric calibration protocols Meets...irements Includes setup information for balances...
...ee plasmid DNA preparations are prepared from cust...1mg to multi-gram scales. Small-scale (1-100mg) a...ons are made according to customer specifications....omer needs, and glycerol stocks are maintained to ...
...ones which belong to the transforming growth facto...arge group of extra-cellular growth factors which ...function and tumor formation (1). Other members in...fferentiation factors, AMH/MIS (Anti-Mullerian Hor...
Biology Products: